Neuroscience
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 7 min read
While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease.
| 10+ min read
Bioelectricity is a potent lever for controlling health. What would it look like to treat the body electrically, rather than chemically?
| 4 min read
For the first time, researchers observed new conformational states between opioid drugs binding to mu opioid receptors — findings that drug developers can use to design safer opioid drugs.
| 2 min read
Aberdeen clinical research centre widens access to clinical trials across Scotland, advancing early Alzheimer’s research
| 4 min read
FDA approvals, rejections, antibody-drug conjugate deals, and more led the news this week.
| 3 min read
Researchers are using caraway seeds to create synthetic cannabidiol compounds for treating seizures.
| 2 min read
FDA greenlights Bayer’s first-in-class drug and non-hormonal option in the vasomotor-symptom space.
| 2 min read
Award-winner Cheng Lyu shows how tiny changes in circuit wiring can shift an animal’s behavior, illuminating the developmental rules of the nervous system.
| 2 min read
Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.
| 1 min read
Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.
| 2 min read
Mini “miBrains” replicate key brain cell types, enabling personalized disease research and drug testing.
